Comprehensive Immuno-Oncology Testing


A Full Suite of Tests for Immunotherapy Biomarkers

Explore More CDx Options with All Currently Available PD-L1 IVDs, Tumor Mutation Burden, MSI, and MMR

NeoGenomics Laboratories is a leader in precision diagnostics and is at the forefront of PD-L1/PD-1 immunotherapy testing. Our broad offering, depth of pathology expertise, and flexible testing options make us an ideal partner for your clinical or research testing needs.

Request Your
Immuno-Oncology Poster

Immuno-Oncology-Poster

Request Now

Immuno-Oncology Assays at NeoGenomics


Test Name & Printable Details Ordering Options
Tumor Mutation Burden (TMB)
  • Included in NeoTYPE® Discovery Profile
  • Add on to any targeted NeoTYPE Solid Tumor Profile
  • Order as stand-alone test
Microsatellite Instability (MSI)
  • Included in NeoTYPE Colorectal, Endometrial, Esophageal, Gastric, GI Predictive, Ovarian, and Pancreas Profiles
  • Add on to any NeoTYPE Solid Tumor Profile
  • Order as stand-alone test
  • Companion diagnostic for KEYTRUDA®1 in certain solid tumors
Mismatch Repair (MMR) IHC
  • With or without digital imaging
  • Technical-only option for client pathologist sign-out
  • Companion diagnostic for KEYTRUDA®1 in certain solid tumors
PD-L1 22C3 FDA (KEYTRUDA®
  • Included in NeoTYPE Solid Tumor Profiles
  • Order as stand-alone test
PD-L1 28-8 FDA (OPDIVO®
PD-L1 SP142 FDA (TECENTRIQ®
PD-L1 SP263 FDA (IMFINZI™) 
  • Order as stand-alone test


Advantages of PD-L1 Testing at NeoGenomics

  • Comprehensive PD-L1 testing with all currently available FDA-approved tests in one location
  • Broad experience as one of the first labs to offer PD-L1 testing, having now reported tens of thousands of results
  • Robust reporting and analysis capabilities under the direction of expert pathologists
  • Flexible ordering options with tech-only service for pathology clients who have completed online vendor training
  • Pharma and Research Services  supporting immunotherapy drug development programs and clinical trials including >100 immuno-oncology clinical projects

 

On-Demand Webinar: PD-L1 Testing in Solid Tumors

Recorded: July 27, 2017

 


PD-L1 IHC Testing for Solid Tumors

PD-L1 testing is an immunohistochemical assay that detects the level and expression sites of PD-L1 protein. As a companion or complementary diagnostic for certain tumors and indications, it helps identify patients for treatments including KEYTRUDA®, OPDIVO®, TECENTRIQ® and IMFINZI™.


Testing for Every Current PD-L1 IHC IVD Assay   

  Clone   Indication Manufacturer FDA-Approved Assay Type Therapy
22C3 NSCLC Dako2 Companion Dx KEYTRUDA® (pembrolizumab)
Gastric/GEA
28-8 NSCLC Dako3 Complementary Dx OPDIVO® (nivolumab)
Melanoma
Head & Neck (SCCHN)
Urothelial Carcinoma
SP142 Urothelial Carcinoma Ventana4 Complementary Dx TECENTRIQ® (atezolizumab)
NSCLC
SP263 Urothelial Carcinoma Ventana5   Complementary Dx IMFINZI™ (durvalumab)

References 
  1. KEYTRUDA® (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc: uspi-mk3475-iv-1709r013
  2. PD-L1 IHC 22C3 pharmDx [package insert]. Carpinteria, CA: Dako; P03951_06/SK006/2017.09
  3. PDL1 IHC 28-8 pharmDx [package insert]. Carpinteria, CA: Dako; P04163_05/SK00521/2017.09
  4. PD-L1 SP142 Assay [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.;1016217US Rev A; 2016-10-21
  5. PD-L1 SP263 Assay [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.; 1014737US Rev A; 2017-04-21